Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Large datasets in paediatric oncology are inherently rare. Therefore, it is paramount to fully exploit all available data, which are distributed over several resources, including biomaterials, images, clinical trials, and registries. With privacy-preserving record linkage (PPRL), personalised or pseudonymised datasets can be merged, without disclosing the patients' identities. Although PPRL is implemented in various settings, use case descriptions are currently fragmented and incomplete. The present paper provides a comprehensive overview of current and future use cases for PPRL in paediatric oncology. We analysed the literature, projects, and trial protocols, identified use cases along a hypothetical patient journey, and discussed use cases with paediatric oncology experts. To structure PPRL use cases, we defined six key dimensions: distributed personalised records, pseudonymisation, distributed pseudonymised records, record linkage, linked data, and data analysis. Selected use cases were described (a) per dimension and (b) on a multi-dimensional level. While focusing on paediatric oncology, most aspects are also applicable to other (particularly rare) diseases. We conclude that PPRL is a key concept in paediatric oncology. Therefore, PPRL strategies should already be considered when starting research projects, to avoid distributed data silos, to maximise the knowledge derived from collected data, and, ultimately, to improve outcomes for children with cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311357PMC
http://dx.doi.org/10.3390/cancers16152696DOI Listing

Publication Analysis

Top Keywords

paediatric oncology
24
record linkage
12
privacy-preserving record
8
cases
6
paediatric
6
oncology
6
pprl
6
data
5
cases requiring
4
requiring privacy-preserving
4

Similar Publications

Compared to adult cancer in Aboriginal and Torres Strait Islander populations, minimal research has focussed on cancer in Indigenous Australian children. This narrative review examined published information about incidence, mortality, barriers to diagnosis and treatment, and psychosocial needs and interventions for Indigenous Australian children with cancer. Most papers were epidemiological, investigating incidence and mortality.

View Article and Find Full Text PDF

Chronic myeloid leukaemia (CML) accounts for 2% of leukaemias in children and 9% in adolescents. While the BCR::ABL1 fusion gene remains a hallmark across all age groups, emerging evidence suggests that paediatric CML exhibits unique biological and clinical characteristics compared to its adult counterpart. Children often present with more aggressive clinical features and show distinct treatment response patterns.

View Article and Find Full Text PDF

This case report concerns a male patient in early adolescence who presented to our clinic with several months of abdominal discomfort, irregular bowel habits, tenesmus and a sensation of incomplete evacuation. Previous treatment was through osmotic laxatives. Initial workup of physical examination and endoscopy was inconclusive and did not show any anatomical abnormalities.

View Article and Find Full Text PDF

Rationale: Cervical cancer is the fourth most common cancer affecting women worldwide, caused by persistent infection with oncogenic human papillomavirus (HPV) types. While HPV infections usually resolve spontaneously, persistent infections with high-risk HPV types can progress to premalignant glandular or - mostly - squamous intraepithelial lesions, usually classified in cervical intraepithelial neoplasia (CIN). Women with CIN 2 and CIN 3 (i.

View Article and Find Full Text PDF

Neuroblastoma is the most common extracranial solid tumor in children, requiring multidisciplinary treatment, including radiotherapy, which is primarily applied in the high-risk group to prevent disease progression. The review highlights indications for radiotherapy, its role in multimodal treatment, and addresses aspects of radiotherapy planning, including target volume definition, prescribed radiation doses, optimal timing for radiotherapy implementation, and potential side effects. Particular attention is drawn to the lack of consensus regarding the necessity of an additional radiation dose for persistent residual disease in the primary tumor and the irradiation of metastatic sites remaining after induction therapy.

View Article and Find Full Text PDF